The US government's supply of remdesivir — the only drug proven to treat the coronavirus — will run out at the end of June
The US government will run out of remdesivir drugs at the end of June, and does not know when it will get more. The Department of Health and Human Services told CNN that Gilead, which makes the drug, will ship a final batch on the week of June 29. "We're waiting to hear from Gilead what is their expected delivery availability of the drug as we go from June to July," Dr. Robert Kadlec told the network. Remdesivir is the only widely-approved COVID-19 treatment, and early studies show it helps mitigate the effect of the virus. All 1.5 million vials of remdesivir that Gilead has in stock are currently in circulation. Gilead says it will get new stocks of crucial raw materials in July, which mean they can make more. Visit Business Insider's homepage for more stories . The US supply of the COVID-19 treatment remdesivir will run out at the end of June, the Department of Health and Human Services has said. Dr. Robert Kadlec, a HHS official, told CNN that Gilead Sciences , which created the drug, will send the government a final shipment the week of June 29, but after that, the HHS does not know when it will get more. "We're waiting to hear from Gilead what is their expected delivery availability of the drug as we go from June to July," Kadlec said.
The US government's supply of remdesivir — the only drug proven to treat the coronavirus — will run out at the end of June
The US government will run out of remdesivir drugs at the end of June, and does not know when it will get more. The Department of Health and Human Services told CNN that Gilead, which makes the drug, will ship a final batch on the week of June 29. "We're waiting to hear from Gilead what is their expected delivery availability of the drug as we go from June to July," Dr. Robert Kadlec told the network. Remdesivir is the only widely-approved COVID-19 treatment, and early studies show it helps mitigate the effect of the virus. All 1.5 million vials of remdesivir that Gilead has in stock are currently in circulation. Gilead says it will get new stocks of crucial raw materials in July, which mean they can make more. Visit Business Insider's homepage for more stories . The US supply of the COVID-19 treatment remdesivir will run out at the end of June, the Department of Health and Human Services has said. Dr. Robert Kadlec, a HHS official, told CNN that Gilead Sciences , which created the drug, will send the government a final shipment the week of June 29, but after that, the HHS does not know when it will get more. "We're waiting to hear from Gilead what is their expected delivery availability of the drug as we go from June to July," Kadlec said.